Savara Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SVRA Nasdaq 2834 www.savarapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Savara Inc.

Savara Announces New Employment Inducement Grant - Apr 17th, 2026 2:05 pm
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Apr 15th, 2026 2:05 pm
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - Apr 14th, 2026 6:05 am
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Apr 7th, 2026 6:05 am
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Mar 30th, 2026 6:05 am
High Growth Tech Stocks To Watch In The US March 2026 - Mar 26th, 2026 5:40 am
VR Adviser Adds Over 1 Million Savara Shares - Mar 15th, 2026 8:59 am
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - Mar 13th, 2026 6:05 am
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Mar 6th, 2026 2:05 pm
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed - Mar 6th, 2026 3:12 am
Savara Announces Participation in 2026 Citizens Life Sciences Conference - Mar 4th, 2026 2:05 pm
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears - Mar 1st, 2026 5:36 pm
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Feb 20th, 2026 2:15 pm
Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit - Feb 15th, 2026 9:03 am
High Growth Tech Stocks To Watch In The US Market - Feb 13th, 2026 4:38 am
Savara Insiders Added US$535.6k Of Stock To Their Holdings - Feb 9th, 2026 4:42 am
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Feb 4th, 2026 2:05 pm
A Look At Hercules Capital (HTGC) Valuation After The Expanded Savara Loan Agreement - Jan 27th, 2026 9:34 pm
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* - Jan 27th, 2026 6:05 am
High Growth Tech Stocks To Watch In The US Market January 2026 - Jan 13th, 2026 4:38 am